Novo Nordisk ® th severe unmet medical needs itive DKK billion Sales of recombinant haemophilia products 40 30 20 10 0 2016 2020 Haemophilia with inhibitors NovoSeven ® Coagil VII Obizur 1 Feiba 2 Hemlibra 3 2016 2020 Haemophilia A NovoEight ® Advate/Adynovate Kogenate/Kovaltry/Jivi Xyntha/Refacto Eloctate/Elocta Helixate/Afstyla Hemlibra 2016 2020 Haemophilia B Refixia ® /Rebinyn ® Idelvion Rixubis Alprolix Benefix 1 Obizur only indicated for acquired haemophilia; 2 Plasma-derived; 3 Part of the Hemlibra sales is used for treatment of haemophilia A patients in 2020 a Source: Company reported sales and Evaluate
Download PDF file